U.S. Markets closed

Adamis Pharmaceuticals Corporation (ADMP)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
4.80+0.15 (+3.23%)
At close: 4:00PM EDT
People also watch
Full screen
Previous Close4.65
Bid4.75 x 300
Ask5.65 x 2200
Day's Range4.70 - 4.95
52 Week Range2.40 - 6.45
Avg. Volume1,355,223
Market Cap132.3M
PE Ratio (TTM)-4.68
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Adamis Gets FDA Nod for Generic Version of Mylan's EpiPen
    Zackslast month

    Adamis Gets FDA Nod for Generic Version of Mylan's EpiPen

    Shares of Adamis Pharmaceuticals Corporation (ADMP) soared more than 50% after the FDA approved the company's Epinephrine injection, USP, (0.3 mg Pre-filled single dose syringe) which is the generic version of Mylan N.V.'s (MYL) EpiPen.

  • TheStreet.comlast month

    Biotech Movers: Adamis Shares Jump After FDA Approves Epinephrine Pre-filled Syringe

    Adamis Pharmaceuticals, Impax Laboratories and Accorda Therapeutics were among the biotech stock movers in premarket trading on June 16.

  • Reuterslast month

    PRESS DIGEST - Wall Street Journal - June 16

    The following are the top stories in the Wall Street Journal. - Nestlé SA put its U.S. confectionery business up for sale, looking to shed its Butterfinger and Crunch candy bars as it grapples with how to cater to U.S. consumers' increasing demand for healthy snacks. - Facebook Inc said that it has expanded its use of artificial intelligence in recent months to identify potential terrorist postings and accounts on its platform—and at times to delete or block them without review by a human.